The Efficacy of Aldehyde Dehydrogenase Enzyme in Essential Tremor Patients: A Single-Center Study
Key facts
- Who runs it
- Pico Entech Co., Ltd.
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 31 people enrolled
- Started
- 10 Mar 2025
- Ended
- 8 Jan 2026
- Type of study
- Interventional
- Treatments tested
- PICOZYME ET
- Record updated
- 29 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Adults aged ≥ 19 years who provide written informed consent
- Diagnosed with Essential Tremor (ET) by a board-certified neurologist or neurosurgeon
- Presence of postural or intention tremor in the dominant hand/arm with a CRST score ≥ 2
- Stable medication regimen for at least 30 days prior to enrollment
- No structural brain abnormalities on MRI within the last 3 years
- Eligible according to investigator assessment and agreement by two clinical team members
Who cannot take part
- Contraindications to MRI (e.g., pacemakers, metal implants)
- Significant medical conditions such as severe arrhythmia, renal failure, hepatic failure, acute stroke, or epilepsy
- Presence of secondary tremor causes (e.g., Parkinsonism, dystonia)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a sponsor-initiated, single-arm, single-center clinical trial designed to evaluate the efficacy and safety of an ALDH-containing food supplement (PICOZYME ET) in patients with Essential Tremor (ET). Participants will consume the investigational product daily for three months, and clinical outcomes will be assessed using the Clinical Rating Scale for Tremor (CRST) and the Activities of Daily Living (ADL) scale. Additional exploratory analyses will evaluate changes in metabolic biomarkers and brain function via imaging and blood tests.
The group in the trial
- ALDH Food SupplementTreatment being tested
Participants in this arm will receive an ALDH-containing food supplement (PICOZYME ET) twice daily for 3 months. The study will assess changes in tremor severity, quality of life, and exploratory metabolic biomarkers.
Treatment: PICOZYME ET
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 29 September 2026